AHC Media - Continuing Medical Education Publishing

The most award winning

healthcare information source.

TRUSTED FOR FOUR DECADES.

  • Sign In
  • Sign Out
  • MyAHC
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Live Webinars
      • On-Demand Webinars
      • Libraries
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Live Webinars
      • On-Demand Webinars
      • Libraries
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Live Webinars
      • On-Demand Webinars
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    Home » The Latest in Genetic Screening for Gynecologic Malignancies
    ABSTRACT & COMMENTARY

    The Latest in Genetic Screening for Gynecologic Malignancies

    April 1, 2018
    No Comments
    Reprints
    Facebook Twitter Linkedin Share Share

    Related Articles

    Urinary and Bowel Symptoms in Women with Suspected Gynecological Malignancy

    Special Feature: Is it Heresy or Good Medicine? HRT in Survivors of Gynecological Malignancies

    Genetic Testing: Who Should Be Tested and What Should They Be Tested For?

    Related Products

    OB/GYN Clinical Alert: Online, 1 Year Subscription

    The Latest CMS Nursing CoPs for 2018

    Pediatric Trauma 2018: Practical Application of the Latest Standards of Care

    Related Events

    Why is Aligning Acute and Post-Acute Care Providers Important in Transitional Planning?

    Bridging the Discharge Gap: Complying with the CMS Discharge Planning Standards and Worksheet

    Crafting the Perfect Collaboration: How do You Align Hospitalists, Physician Advisors, ED Physicians, and Other Heavy Hitters?

    Keywords

    Cancer

    Genetics

    gynecologic

    By Molly A. Brewer, DVM, MD, MS

    Professor and Chair, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Connecticut Health Center, Farmington

    Dr. Brewer reports no financial relationships relevant to this field of study.

    SYNOPSIS: Genetic testing is changing rapidly. With the advent of more sophisticated genetic mutation panels, it is important that providers of women’s healthcare consider appropriate referral and testing for those women at increased risk of malignancy.

    SOURCE: Ring KL, Garcia C, Thomas MH, Modesitt SC. Current and future role of genetic screening in gynecologic malignancies. Am J Obstet Gynecol 2017;217:512-521.

    With the advent of new panels screening for genetic oncologic mutations and as first-line clinicians for women, gynecologists need to be aware of the changes that have occurred over the last two years in genetic testing. As outlined by Ring et al, the current recommendation is panel testing for women with a strong family history of gynecologic cancers, such as ovarian or endometrial cancer, and a personal history of breast, ovarian, or endometrial cancer. Since Myriad Genetics lost its patent on the BRCA genes,1 many companies now offer genetic panels that test for a number of genes that only recently have been associated with gynecologic and breast cancers. Even five years ago, ovarian cancer was thought to be associated only with a deleterious germline mutation 5-10% of the time. As these authors note, approximately 24% of ovarian cancers are associated with a germline mutation.2 Unfortunately, there still is not consistent identification of women at risk for germline mutations nor consistent referral for testing for these mutations.3

    Although BRCA1 and BRCA2 are the more commonly recognized gene mutations, multiple other pathways may carry germline mutations leading to gynecologic cancers. One pathway leads to acquisition of Lynch syndrome (also known as hereditary nonpolyposis colorectal cancer). Lynch syndrome is responsible for approximately 15% of hereditary ovarian cancers, which often histologically are endometrioid or clear cell cancers. These women are at increased risk of colorectal, endometrial, gastric, small bowel, genitourinary, pancreatic, and glioblastoma cancers. Approximately 8% of all endometrial cancers are associated with Lynch syndrome.

    In addition to BRCA1 and BRCA2 mutations, other mutations of DNA repair pathways affect RAD51C, RAD51D, and BRIP1, which may carry a 10% lifetime risk of ovarian cancer.4 PALB2 and BARD1 are associated with an increased risk of breast cancer, but have not been associated with ovarian cancer.

    Another identifiable oncologic gene mutation is the one associated with PTEN (Cowden syndrome). Women with these mutations have up to a 28% risk of endometrial cancer as well as hamartomas, which usually are benign lesions. POLD1, which works with the Lynch syndrome genes, has an increased risk of both endometrial and colon cancer.5 Women with a BRCA1 mutation have an increased risk of serous endometrial cancer.6 Women with adenoma malignum of the cervix may have Peutz-Jeghers syndrome, and young women with rhabdomyosarcoma may carry a DICER1 mutation. These women should be considered for genetic testing. These are all examples of gynecologic cancers associated with identifiable gene mutations.

    COMMENTARY

    So how can women’s health providers keep these new germline mutations straight? The most important aspect of patient care in a suspected patient is to take a careful family history and make appropriate referrals to one of several practitioners, depending on the individual’s needs.7 If you have access to a cancer genetic counselor, it is more appropriate to refer patients for genetic counseling and appropriate testing, because genetic counselors are more up-to-date on what to test for as well as how to counsel patients.

    Barriers to genetic testing are mainly due to the lack of consistent information on the importance of genetic testing.8 If you do not have access to genetic counselors, panel testing is a reasonable alternative. However, prior to making treatment recommendations, it would be prudent to seek help about how to counsel patients on interpretation of the test results. A surgical oncologist can better counsel on appropriate breast cancer strategies and a gynecologic oncologist can better counsel on appropriate gynecologic strategies. Removing a woman’s ovaries and tubes before she has children probably is not in the patient’s best interest, even if her gene panel is positive. This requires delicate counseling and screening recommendations. However, increased screening may be appropriate for both breast and ovarian cancer, depending on the mutation discovered.

    One of the errors I see routinely is the referral of a patient with a mutation that is considered a variant of uncertain significance for prophylactic surgery. It is not appropriate to recommend prophylactic surgery unless the variant is reclassified as a deleterious mutation. Again, this is better managed with the help of genetic counselors who routinely communicate with the companies that follow these mutations and reclassify those mutations as deleterious if they track with clusterings of cancer. If they are reclassified as benign polymorphisms, then the patient not only does not need prophylactic surgery, she does not need increased surveillance.

    The world of cancer-associated mutations has changed dramatically in the last 10 years and we expect it to continue to do so. To keep up with new findings, it is important to have a relationship with a genetic counselor and a gynecologic oncologist who can help sort through these new changes.

    REFERENCES

    1. Servick K. End of the road for Myriad gene patent fight. Science Available at: http://www.sciencemag.org/news/2015/01/end-road-myriad-gene-patent-fight. Accessed Feb. 23, 2018.
    2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7-30.
    3. Hoskins PJ, Gotlieb WH. Missed therapeutic and prevention opportunities in women with BRCA-mutated epithelial ovarian cancer and their families due to low referral rates for genetic counseling and BRCA testing: A review of the literature. CA Cancer J Clin 2017;67:493-506.
    4. Ramus SJ, Song H, Dicks E, et al. Germline mutations in the BRIP1, BARD1, PALB2, and NBN genes in women with ovarian cancer. J Natl Cancer Inst 2015;107:djv214.
    5. Palles C, Cazier JB, Howarth KM, et al. Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nat Genet 2013;45:136-144.
    6. Shu CA, Pike MC, Jotwani AR, et al. Uterine cancer after risk-reducing salpingo-oophorectomy without hysterectomy in women with BRCA mutations. JAMA Oncol 2016;2:1434-1440.
    7. Committee on Gynecologic Practice, Society of Gynecologic Oncology. Committee Opinion No. 716: The role of the obstetrician-gynecologist in the early detection of epithelial ovarian cancer in women at average risk. Obstet Gynecol 2017;130:e146-e149.
    8. Shaw J, Bulsara C, Cohen PA, et al. Investigating barriers to genetic counseling and germline mutation testing in women with suspected hereditary breast and ovarian cancer syndrome and Lynch syndrome. Patient Educ Couns 2017; Dec. 12. pii: S0738-3991(17)30657-2. doi: 10.1016/j.pec.2017.12.011. [Epub ahead of print].

    Post a comment to this article

    Report Abusive Comment

    www.ahcmedia.com

    OB/GYN Clinical Alert

    View PDF
    OB/GYN Clinical Alert (Vol. 34, No. 12) – April 2018
    April 1, 2018

    Table Of Contents

    Induction of Labor at 39 Weeks

    Obesity and Prolapse: Are They Related?

    Breast MRI Exams Increase the Biopsy Rate Without Improving Cancer Detection

    The Latest in Genetic Screening for Gynecologic Malignancies

    Begin Test

    Buy this Issue/Course

    Clinical Briefs in Primary Care

    Pharmacology Watch

    Feedback? Take Our Quick Reader Survey

    Financial Disclosure: OB/GYN Clinical Alert’s Editor, Jeffrey T. Jensen, MD, MPH, reports that he is a consultant for and receives grant/ research support from Bayer, Merck, ContraMed, and FHI360; he receives grant/research support from Abbvie, HRA Pharma, Medicines 360, and Conrad; and he is a consultant for the Population Council. Peer Reviewer Catherine Leclair, MD; Nurse Planners Marci Messerle Forbes, RN, FNP, and Andrea O’Donnell, FNP; Editorial Group Manager Terrey L. Hatcher; Executive Editor Leslie Coplin; and Editor Journey Roberts report no financial relationships relevant to this field of study.

    Shop Now: Search Products

    • Subscription Publications
    • Books & Study Guides
    • Group & Site
      Licenses
    • Upcoming Live Webinars
    • On-Demand Webinars
    • State CME/CE
      Requirements

    Webinars And Events

    EMTALA Series

    Apr 24 2018, 3:30pm EDT
    Live Webinar

    Preventing Medication Errors: 60+ Tips to Implement Today

    Apr 25 2018, 3:30pm EDT
    Live Webinar

    Pain Management 101: CMS Opioid, IV Medication, and Blood Transfusion Guidelines

    May 1 2018, 3:30pm EDT
    Live Webinar
    View All Events

    Free Email Newsletters

    • Accreditation Council for Continuing Medical Education
    • American Nurses Credentialing Center
    • American College of Emergency Physician
    • American Board of Internal Medicine: Maintenance of Certification
    • California Board of Registered Nursing
    • Commission for Case Manager Certification
    • American Academy of Pediatrics
    • American Osteopathic Association
    • Stand Up for Kids
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Live Webinars
      • On-Demand Webinars
      • Libraries
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Live Webinars
      • On-Demand Webinars
      • Libraries
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Live Webinars
      • On-Demand Webinars
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    • Help
    • Search
    • About Us
    • Sign In
    • Register
    AHC Media - Continuing Medical Education Publishing

    The most award winning

    healthcare information source.

    TRUSTED FOR FOUR DECADES.

    Customer Service

    Customer.Service@AHCMedia.com

    U.S. and Canada: 1-800-688-2421

    International +1-404-262-5476

    Accounts Receivable

    1-800-370-9210
    ahcmedia_ar@reliaslearning.com

    Mailing Address

    • 111 Corning Road, Suite 250
      Cary, NC 27518
      USA

    © 2018 Relias. All rights reserved.

    Privacy Policy  Terms of Use  Contact Us  Reprints  Group Sales

    Design, CMS, Hosting & Web Development :: ePublishing